Literature DB >> 17016557

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Michael R Mancuso1, Rachel Davis, Scott M Norberg, Shaun O'Brien, Barbara Sennino, Tsutomu Nakahara, Virginia J Yao, Tetsuichiro Inai, Peter Brooks, Bruce Freimark, David R Shalinsky, Dana D Hu-Lowe, Donald M McDonald.   

Abstract

Inhibitors of VEGF signaling can block angiogenesis and reduce tumor vascularity, but little is known about the reversibility of these changes after treatment ends. In the present study, regrowth of blood vessels in spontaneous RIP-Tag2 tumors and implanted Lewis lung carcinomas in mice was assessed after inhibition of VEGF receptor signaling by AG-013736 or AG-028262 for 7 days. Both agents caused loss of 50%-60% of tumor vasculature. Empty sleeves of basement membrane were left behind. Pericytes also survived but had less alpha-SMA immunoreactivity. One day after drug withdrawal, endothelial sprouts grew into empty sleeves of basement membrane. Vessel patency and connection to the bloodstream followed close behind. By 7 days, tumors were fully revascularized, and the pericyte phenotype returned to baseline. Importantly, the regrown vasculature regressed as much during a second treatment as it did in the first. Inhibition of MMPs or targeting of type IV collagen cryptic sites by antibody HUIV26 did not eliminate the sleeves or slow revascularization. These results suggest that empty sleeves of basement membrane and accompanying pericytes provide a scaffold for rapid revascularization of tumors after removal of anti-VEGF therapy and highlight their importance as potential targets in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016557      PMCID: PMC1578604          DOI: 10.1172/JCI24612

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells.

Authors:  Iiro Rajantie; Maritta Ilmonen; Agne Alminaite; Ugur Ozerdem; Kari Alitalo; Petri Salven
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

2.  Schwann cell basal lamina and nerve regeneration.

Authors:  C Ide; K Tohyama; R Yokota; T Nitatori; S Onodera
Journal:  Brain Res       Date:  1983-12-12       Impact factor: 3.252

3.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

4.  Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels.

Authors:  Fabienne Baffert; Gavin Thurston; Michael Rochon-Duck; Tom Le; Rolf Brekken; Donald M McDonald
Journal:  Circ Res       Date:  2004-03-04       Impact factor: 17.367

5.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors.

Authors:  Peter Baluk; Shunichi Morikawa; Amy Haskell; Michael Mancuso; Donald M McDonald
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade.

Authors:  Haiqing Li; William L Gerald; Robert Benezra
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Authors:  K A Houck; D W Leung; A M Rowland; J Winer; N Ferrara
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

9.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

Authors:  Tetsuichiro Inai; Michael Mancuso; Hiroya Hashizume; Fabienne Baffert; Amy Haskell; Peter Baluk; Dana D Hu-Lowe; David R Shalinsky; Gavin Thurston; George D Yancopoulos; Donald M McDonald
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  Basal lamina: the scaffold for orderly cell replacement. Observations on regeneration of injured skeletal muscle fibers and capillaries.

Authors:  R Vracko; E P Benditt
Journal:  J Cell Biol       Date:  1972-11       Impact factor: 10.539

View more
  304 in total

1.  FGF-dependent regulation of VEGF receptor 2 expression in mice.

Authors:  Masahiro Murakami; Loc T Nguyen; Kunihiko Hatanaka; William Schachterle; Pei-Yu Chen; Zhen W Zhuang; Brian L Black; Michael Simons
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Authors:  Rodrigo Dienstmann; Felipe Ades; Kamal S Saini; Otto Metzger-Filho
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

3.  Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.

Authors:  Yanping Ding; Nan Song; Yongzhang Luo
Journal:  Cancer Microenviron       Date:  2012-04-20

Review 4.  Bevacizumab.

Authors:  Filis Kazazi-Hyseni; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2010-08-05

Review 5.  The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.

Authors:  Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Stephanos Pavlides; Barbara Chiavarina; Gloria Bonuccelli; Trimmer Casey; Aristotelis Tsirigos; Gemma Migneco; Agnieszka Witkiewicz; Renee Balliet; Isabelle Mercier; Chengwang Wang; Neal Flomenberg; Anthony Howell; Zhao Lin; Jaime Caro; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-11-30       Impact factor: 4.534

6.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.

Authors:  Emmanuelle di Tomaso; Matija Snuderl; Walid S Kamoun; Dan G Duda; Pavan K Auluck; Ladan Fazlollahi; Ovidiu C Andronesi; Matthew P Frosch; Patrick Y Wen; Scott R Plotkin; E Tessa Hedley-Whyte; A Gregory Sorensen; Tracy T Batchelor; Rakesh K Jain
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

7.  Peering into the aftermath: The inhospitable host?

Authors:  Robert S Kerbel; John M L Ebos
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

Review 8.  Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.

Authors:  Eva Ciruelos; José Manuel Pérez-García; Joaquín Gavilá; Analía Rodríguez; Juan de la Haba-Rodriguez
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

9.  Ultrasound Evaluation of Anti-Vascular Endothelial Growth Factor-Induced Changes in Vascular Response Following Tendon Injury.

Authors:  Corinne N Riggin; Susan M Schultz; Chandra M Sehgal; Louis J Soslowsky
Journal:  Ultrasound Med Biol       Date:  2019-04-30       Impact factor: 2.998

Review 10.  Customizable biomaterials as tools for advanced anti-angiogenic drug discovery.

Authors:  Eric H Nguyen; William L Murphy
Journal:  Biomaterials       Date:  2018-07-26       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.